Profil
Ola Melin is currently the Chief Operating Officer at Circio Holding ASA. Prior to this role, she worked as the Director of Technical Operations at OxThera AB and as the Director of Extended Manufacturing at Swedish Orphan Biovitrum AB.
Ms. Melin completed her undergraduate degree at Mälardalen University.
Aktive Positionen von Ola Melin
Unternehmen | Position | Beginn |
---|---|---|
CIRCIO HOLDING ASA | Geschäftsführer | - |
Ehemalige bekannte Positionen von Ola Melin
Unternehmen | Position | Ende |
---|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Technik-/Wissenschafts-/F&E-Leiter | - |
SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | - |
Ausbildung von Ola Melin
Mälardalen University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
CIRCIO HOLDING ASA | Health Technology |
Private Unternehmen | 1 |
---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |